ETRA
ETRA clinical trials: Electra Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Electra Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 3
- Trials linked
- 3
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ETRA on the catalyst calendar · ETRA registry changes
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Mar 2028Sponsor estimate | NCT05416307Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)Electra Therapeutics Inc. · Secondary Hemophagocytic Lymphohistiocytosis (sHLH) | ETRALead | Phase 2/Phase 3 | Recruiting | Locked | Locked | Locked |
| Jun 2028Sponsor estimate | NCT07465835A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)Electra Therapeutics Inc. · T Cell Malignancies | ETRALead | Phase 1 | Recruiting | Locked | Locked | Locked |
| Nov 20, 2023Actual | NCT05556863Evaluation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ELA026 in Single and Multiple Doses in Healthy VolunteersElectra Therapeutics Inc. · Healthy Volunteers | ETRALead | Phase 1 | Completed | Locked | Locked | Locked |
- Primary completion Mar 2028Sponsor estimatePhase 2/Phase 3NCT05416307Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)Electra Therapeutics Inc. · Secondary Hemophagocytic Lymphohistiocytosis (sHLH)RecruitingETRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2028Sponsor estimatePhase 1NCT07465835A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)Electra Therapeutics Inc. · T Cell MalignanciesRecruitingETRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 20, 2023ActualPhase 1NCT05556863Evaluation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ELA026 in Single and Multiple Doses in Healthy VolunteersElectra Therapeutics Inc. · Healthy VolunteersCompletedETRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 3 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner